- Home
- BW vs ZNTL Comparison
BW vs ZNTL Comparison
Compare BW & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BW
- ZNTL
- Stock Information
- Founded
- BW 1867
- ZNTL 2014
- Country
- BW United States
- ZNTL United States
- Employees
- BW N/A
- ZNTL N/A
- Industry
- BW Building Products
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- BW Industrials
- ZNTL Health Care
- Exchange
- BW Nasdaq
- ZNTL Nasdaq
- Market Cap
- BW 95.7M
- ZNTL 105.8M
- IPO Year
- BW N/A
- ZNTL 2020
- Fundamental
- Price
- BW $1.03
- ZNTL $1.36
- Analyst Decision
- BW Buy
- ZNTL Buy
- Analyst Count
- BW 2
- ZNTL 7
- Target Price
- BW $3.50
- ZNTL $8.60
- AVG Volume (30 Days)
- BW 839.8K
- ZNTL 1.4M
- Earning Date
- BW 08-07-2025
- ZNTL 08-08-2025
- Dividend Yield
- BW N/A
- ZNTL N/A
- EPS Growth
- BW N/A
- ZNTL N/A
- EPS
- BW N/A
- ZNTL N/A
- Revenue
- BW $734,239,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- BW $5.81
- ZNTL N/A
- Revenue Next Year
- BW $9.24
- ZNTL N/A
- P/E Ratio
- BW N/A
- ZNTL N/A
- Revenue Growth
- BW 12.90
- ZNTL N/A
- 52 Week Low
- BW $0.22
- ZNTL $1.01
- 52 Week High
- BW $2.99
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- BW 54.12
- ZNTL 53.17
- Support Level
- BW $0.99
- ZNTL $1.29
- Resistance Level
- BW $1.10
- ZNTL $1.38
- Average True Range (ATR)
- BW 0.07
- ZNTL 0.10
- MACD
- BW -0.01
- ZNTL 0.01
- Stochastic Oscillator
- BW 58.18
- ZNTL 77.97
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.